An update on exacerbation in COPD

Minerva Pneumologica

Volumn 50, Issue 2, 2011, Pages 129-146

  Scherr, A ^a   Blasi, F ^b   Stolz, D ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Antibiotics; Disease progression; Pulmonary disease, chronic obstructive

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BIOLOGICAL MARKER; DOXYCYCLINE; ERYTHROMYCIN; METHYLPREDNISOLONE; MOXIFLOXACIN; OFLOXACIN; PREDNISOLONE; PROCALCITONIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG TREATMENT FAILURE; DRUG USE; HUMAN; PATIENT SELECTION; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; VIRUS INFECTION;

EID: 79960997283     PISSN: 00264954     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412. (Pubitemid 43180921)
2. Fabbri LM, Hurd SS. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003;22:1-2.
3. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels Thromb Haemost 2000;84:210-5.
4. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998;158:1277-85.
5. Groenewegen KH, Wouters EF. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med 2003;97:770-7. (Pubitemid 36763889)
6. Fletcher CM. Letter: Natural history of chronic bronchitis. Br Med J 1976;1:1592-3.
7. [No authors listed]. Deaths from chronic obstructive pulmonary disease - United States, 2000-2005. MMWR Morb Mortal Wkly Rep 2008;57:1229-32.
8. Rivera-Fernandez R, Navarrete-Navarro P, Fernandez-Mondejar E, Rodriguez-Elvira M, Guerrero-Lopez F, Vazquez-Mata G. Six-year mortality and quality of life in critically ill patients with chronic obstructive pulmonary disease. Crit Care Med 2006;34:2317-24. (Pubitemid 44260015)
9. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:245-51. (Pubitemid 43668189)
10. Sethi S, Mallia P, Johnston SL. New paradigms in the pathogenesis of chronic obstructive pulmonary disease II. Proc Am Thorac Soc 2009;6:532-4.
11. Proud D, Chow CW. Role of viral infections in asthma and chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2006;35:513-8. (Pubitemid 44706423)
12. Kim EY, Battaile JT, Patel AC, You Y, Agapov E, Grayson MH et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 2008;14:633-40.
13. Upshur RE, Moineddin R, Crighton EJ, Mamdani M. Interactions of viral pathogens on hospital admissions for pneumonia, croup and chronic obstructive pulmonary diseases: results of a multivariate timeseries analysis. Epidemiol Infect 2006;134:1174-8. (Pubitemid 44614937)
14. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355-65.
15. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352:1749-59. (Pubitemid 40570923)
16. Gencay M, Roth M, Christ-Crain M, Mueller B, Tamm M, Stolz D. Single and multiple viral infections in lower respiratory tract infection. Respiration 2010;80:560-7.
17. McManus TE, Marley AM, Baxter N, Christie SN, O'Neill HJ, Elborn JS et al. Respiratory viral infection in exacerbations of COPD. Respir Med 2008;102:1575-80.
18. Cameron RJ, de Wit D, Welsh TN, Ferguson J, Grissell TV, Rye PJ. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med 2006;32:1022-9.
19. Djukanovic R, Gadola SD. Virus infection, asthma, and chronic obstructive pulmonary disease. N Engl J Med 2008;359:2062-4.
20. Hurst JR, Donaldson GC, Wilkinson TM, Perera WR, Wedzicha JA. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J 2005;26:846-52. (Pubitemid 41632041)
21. Clinicaltrials.gov. [cited 2011 April H]. Available at: http://clinicaltrials.gov/.
22. Wilkinson TM, Donaldson GC, Johnston SL, Open-shaw PJ, Wedzicha JA et al. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:871-6.
23. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(1):CD002733.
24. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:1224-38. (Pubitemid 46895385)
25. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71. (Pubitemid 34879333)
26. Ko FW, Ng TK, Li TS, Fok JP, Chan MC, Wu AK et al. Sputum bacteriology in patients with acute exacerbations of COPD in Hong Kong. Respir Med 2005;99:454-60.
27. Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997;112(6 Suppl):310S-3S.
28. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001;358:2020-5. (Pubitemid 34084824)
29. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116:40-6. (Pubitemid 29340258)
30. Allegra L, Blasi F, de Bernardi B, Cosentini R, Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a reevaluation of previously published data of a placebocontrolled randomized study. Pulm Pharmacol Ther 2001;14:149-55. (Pubitemid 32553620)
31. Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003;58:37-42. (Pubitemid 36135356)
32. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57:759-64. (Pubitemid 34984972)
33. Rosell A, Monso E, Soler N, Torres F, Angrill J, Riise G et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005;165:891-7. (Pubitemid 40563235)
34. Miravitlles M, Marin A, Monso E, Vila S, de la Roza C, Hervas R et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respir Res 2010;11:58.
35. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-47.
36. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11:10.
37. Gold PM. The 2007 GOLD Guidelines: a comprehensive care framework. Respir Care 2009;54:1040-9.
38. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46. (Pubitemid 38807371)
39. Tsoumakidou M, Tzanakis N, Voulgaraki O, Mitrouska I, Chrysofakis G, Samiou M et al. Is there any correlation between the ATS, BTS, ERS and GOLD COPD's severity scales and the frequency of hospital admissions? Respir Med 2004;98:178-83.
40. Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004;98:99-107. (Pubitemid 38181126)
41. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
42. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008;177:396-401. (Pubitemid 351317582)
43. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34:648-54.
44. Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 2010;13:965-75.
45. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13. (Pubitemid 30329036)
46. Bhowmik A, Seemungal TA, Donaldson GC, Wedzicha JA. Effects of exacerbations and seasonality on exhaled nitric oxide in COPD. Eur Respir J 2005;26:1009-15.
47. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20. (Pubitemid 30245950)
48. Powrie DJ, Hurst JR. Breathing new life into respiratory medicine? Report of the 2004 BTS Winter Meeting. Thorax 2005;60:183-6.
49. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:446-52. (Pubitemid 40444244)
50. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carre P, Perez T et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009;135:975-82.
51. Foreman MG, DeMeo DL, Hersh CP, Reilly JJ, Silverman EK. Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J 2007;30:1124-30.
52. Marin JM, Carrizo SJ, Casanova C, Martinez-Camblor P, Soriano JB, Agusti AG et al. Prediction of risk of COPD exacerbations by the BODE index. Respir Med 2009;103:373-8.
53. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between depression and exacerbations in COPD. Eur Respir J 2008;32:53-60.
54. Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007;131:20-8. (Pubitemid 46122970)
55. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:853-60. (Pubitemid 351600663)
56. Rascon-Aguilar IE, Pamer M, Wludyka P, Cury J, Coultas D, Lambiase LR et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 2006;130:1096-101.
57. Terada K, Muro S, Sato S, Ohara T, Haruna A, Marumo S et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 2008;63:951-5.
58. Casanova C, Baudet JS, del Valle Velasco M, Martin JM, Aguirre-jaime A, de Torres JP et al. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J 2004;23:841-5.
59. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;167:950-5.
60. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008;31:869-73.
61. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
62. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204. (Pubitemid 17009877)
63. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003;10(Suppl B):3B-32B.
64. Calverley PM et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. (Pubitemid 46294610)
65. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
66. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C, Hendrix R. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2004;39:980-6.
67. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131:9-19.
68. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-23. (Pubitemid 33124148)
69. Llor C, Miravitlles M. More evidence is required for short-term treatment of exacerbations of chronic obstructive pulmonary disease: 3 days or no antibiotic at all? Clin Microbiol Infect 2007;13:748-9.
70. Roede BM, Bresser P, Bindels PJ, Kok A, Prins M, ter Riet G et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease, an historical population based cohort study. Thorax 2008;63:968-73-
71. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M et al. Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res 2006;7:74.
72. Chhajed PN, Aboyoun C, Chhajed TP, Malouf MA, Harrison GA, Tamm M et al. Sedative drug requirements during bronchoscopy are higher in cystic fibrosis after lung transplantation. Transplantation 2005;80:1081-5. (Pubitemid 41611931)
73. Roche N, Kouassi B, Rabbat A, Mounedji A, Lorut C, Huchon G. Yield of sputum microbiological examination in patients hospitalized for exacerbations of chronic obstructive pulmonary disease with purulent sputum. Respiration 2007;74:19-25. (Pubitemid 46012444)
74. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45. (Pubitemid 30413357)
75. Soler N, Agusti C, Angrill J, Puig De la Bellacasa J, Torres A. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007;62:29-35. (Pubitemid 46101763)
76. Daniels JM, de Graaff CS, Vlaspolder F, Snijders D, Jansen HM, Boersma WG. Sputum colour reported by patients is not a reliable marker of the presence of bacteria in acute exacerbations of chronic obstructive pulmonary disease. Clin Microbiol Infect 2010;16:583-8.
77. Allegra L, Blasi F, Diano P, Cosentini R, Tarsia P, Confalonieri M et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 2005;99:742-7.
78. Stockley RA, Bayley D, Hill SL, Hill AT, Crooks S, Campbell EJ. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001;56:366-72. (Pubitemid 32398127)
79. Burley CJ, Masterton RG, Lovell DP. Indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs. J Infect 2007;55:226-32. (Pubitemid 47244922)
80. Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, Telgen MC, van der Palen J, Hendrix MG et al. Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med 2009;103:601-6.
81. Woodhead M, Gialdroni Grassi G, Huchon GJ, Leophonte P, Manresa F, Schaberg T. Use of investigations in lower respiratory tract infection in the community: a European survey. Eur Respir J 1996;9:1596-600.
82. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117(5 Suppl 2):380S-5S.
83. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-21. (Pubitemid 43726892)
84. [No authors listed]. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
85. Lacoma A, Prat C, Andreo F, Dominguez J. Biomarkers in the management of COPD. Eur Respir Rev 2009;18:96-104.
86. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-74. (Pubitemid 44564786)
87. Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:269-78. (Pubitemid 351198369)
88. Stolz D, Breidthardt T, Christ-Crain M, Bingisser R, Miedinger D, Leuppi J et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008;133:1088-94. (Pubitemid 351685510)
89. Bernasconi M, Tamm M, Bingisser R, Miedinger D, Leuppi J, Muller B et al. Midregional pro-atrial natriuretic peptide predicts survival in exacerbations of COPD. Chest 2010 [Epub ahead of print].
90. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131:1058-67.
91. Stolz D, Christ-Crain M, Morgenthaler NG, Miedinger D, Leuppi J, Muller C et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008;134:263-72.
92. Weis N, Almdal T. C-reactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med 2006;17:88-91.
93. Stolz D, Christ-Crain M, Gencay MM, Bingisser R, Huber PR, Muller B et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly 2006;136:434-40. (Pubitemid 44174759)
94. Becker KL, Nylen ES, White JC, Muller B, Snider RH, Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89:1512-25. (Pubitemid 38507896)
95. Nseir S, Cavestri B, Di Pompeo C, Diarra M, Brisson H, Lemyze M et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008;76:253-60.
96. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302:1059-66.
97. Daniels JM, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010;138:1108-15.
98. Manresa F, Blavia R, Martin R, Linares J, Rodriguez B, Verdaguer R. Antibiotics for exacerbations of chronic bronchitis. Lancet 1987;2:394-5.
99. Jorgensen AF, Coolidge J, Pedersen PA, Petersen KP, Waldorff S, Widding E. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice. Scand J Prim Health Care 1992;10:7-11.
100. Pines A, Raafat H, Greenfield JS, Linsell WD, Solari ME. Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis. Br J Dis Chest 1972;66:107-15.
101. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010;303:2035-42.
102. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(2):CD004403.
103. Puhan MA, Vollenweider D, Latshang T, Steurer J, Steurer-Stey C. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007;8:30.
104. Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004;125:953-64. (Pubitemid 38367286)
105. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:150-7.
106. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:150-7.
107. Wilson R, Jones P, Schaberg T, Arvis P, DupratLomon I, Sagnier PP. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006;61:337-42.
108. Wilson R. Short course of antibiotic treatment in acute exacerbations of COPD. Thorax 2008;63:390-2. (Pubitemid 351692342)
109. Canut A, Martin-Herrero JE, Labora A, Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J Antimicrob Chemother 2007;60:605-12. (Pubitemid 47299876)
110. El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008;63:415-22. (Pubitemid 351692349)
111. Dimopoulos G, Siempos, II, Korbila IP, Manta KG, Falagas ME. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007;132:447-55. (Pubitemid 47282375)
112. Miravitlles M, Murio C, Guerrero T, Segu JL. [Treatment of chronic bronchitis and chronic pulmonary obstructive disease in primary care]. Arch Bronconeumol 1999;35:173-8.
113. Miravitlles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother 2005;6:283-93. (Pubitemid 40305340)
114. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999;354:456-60. (Pubitemid 29368923)
115. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941-7.
116. Emerman CL, Connors AF, Lukens TW, May ME, Effron D. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest 1989;95:563-7. (Pubitemid 19094445)
117. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348:2618-25. (Pubitemid 36741589)
118. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980;92:753-8. (Pubitemid 10124358)
119. Walters JA, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009;(1):CD001288.
120. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154(2 Pt 1):407-12. (Pubitemid 26269111)
121. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124:459-67. (Pubitemid 37000120)
122. Schuetz P, Leuppi JD, Tamm M, Briel M, Bingisser R, Durring U et al. Short versus conventional term glucocorticoid therapy in acute exacerbation of chronic obstructive pulmonary disease - the "REDUCE" trial. Swiss Med Wkly 2010;140:13109.
123. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA 2010;303:2359-67.
124. Harrison BD, Stokes TC, Hart GJ, Vaughan DA, Ali NJ, Robinson AA. Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. Lancet 1986;1:181-4. (Pubitemid 16135516)
125. Jonsson S, Kjartansson G, Gislason D, Helgason H. Comparison of the oral and intravenous routes for treating asthma with methylprednisolone and theophylline. Chest 1988;94:723-6.
126. Ratto D, Alfaro C, Sipsey J, Glovsky MM, Sharma OP. Are intravenous corticosteroids required in status asthmaticus? JAMA 1988;260:527-9.
127. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333:817-22.
128. Ram FS, Picot J, Lightowler J, Wedzicha JA. Noninvasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004;(3):CD004104.
129. Keenan SP, Sinuff T, Cook DJ, Hill NS. Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature. Ann Intern Med 2003;138:861-70.
130. Tobin MJ. Mechanical ventilation. N Engl J Med 1994;330:1056-61. (Pubitemid 24106565)
131. Keenan SP, Powers CE, McCormack DG. Noninvasive positive-pressure ventilation in patients with milder chronic obstructive pulmonary disease exacerbations: a randomized controlled trial. Respir Care 2005;50:610-6. (Pubitemid 46190329)
132. Demoule A, Girou E, Richard JC, Taille S, Brochard L. Increased use of noninvasive ventilation in French intensive care units. Intensive Care Med 2006;32:1747-55.
133. Nava S, Carlucci A. Support ventilation versus conventional oxygen. Lancet 2001;357:1126-7.
134. Drummond J, Rowe B, Cheung L, Mayers I. The use of noninvasive mechanical ventilation for the treatment of acute exacerbations of chronic obstructive pulmonary disease in Canada. Can Respir J 2005;12:129-33. (Pubitemid 40766818)
135. Burns KE, Sinuff T, Adhikari NK, Meade MO, Heels-Ansdell D, Martin CM et al. Bilevel noninvasive positive pressure ventilation for acute respiratory failure: survey of Ontario practice. Crit Care Med 2005;33:1477-83. (Pubitemid 40980601)
136. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002;287:345-55. (Pubitemid 34251968)
137. Maggiore SM, Richard JC, Abroug F, Diehl JL, Antonelli M, Sauder P et al. A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease. Crit Care Med 2010;38:145-51.